Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...

AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU).

AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...

AstraZeneca plc. AZN announced that the Japanese regulatory authority has granted marketing approval to its SGLT2 inhibitor Forxiga for a new indication — as an oral adjunct treatment to insulin in ...

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without ...

AstraZeneca plcAZN announced that the European Commission (EC) has approved a label expansion of its diabetes drug, Forxiga (dapagliflozin). Forxiga has been approved for the treatment of type-1 ...

AstraZeneca PLC AZN announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the marketing approval for ...

AstraZeneca and Bristol-Myers Squibb are celebrating following the approval of their diabetes drug Forxiga in the European Union. AstraZeneca and Bristol-Myers Squibb are celebrating following the ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w2pvcl/forxiga_type_2) has announced the addition of the "Global Forxiga ...

(RTTNews) - AstraZeneca Plc (AZN.L, AZN) announced Wednesday that Forxiga has received approval in Japan for Type-1 Diabetes or T1D. The Japanese Ministry of Health, Labour and Welfare or MHLW has ...

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...